TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by
CTG
in
Recurrent B-Cell Non-Hodgkin Lymphoma,
Recurrent ALK Positive Large B-Cell Lymphoma,
Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation,
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified,
Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites